Høreklinikken Maribo ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Bankruptcy risk for industry  3.6% 3.6% 3.6% 3.6% 3.6%  
Bankruptcy risk  9.7% 17.9% 14.6% 12.1% 11.9%  
Credit score (0-100)  27 8 13 19 19  
Credit rating  BB B BB BB BB  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4

Net sales  0 0 0 0 0  
Gross profit  11.3 0.8 -13.0 -21.9 -21.5  
EBITDA  11.3 0.8 -13.0 -21.9 -21.5  
EBIT  11.3 0.8 -13.0 -21.9 -21.5  
Pre-tax profit (PTP)  7.7 -2.1 -19.0 -28.2 -27.3  
Net earnings  14.1 -2.1 -15.2 -2.9 -21.3  
Pre-tax profit without non-rec. items  7.7 -2.1 -19.0 -28.2 -27.3  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -105 -107 -85.0 -88.0 -109  
Interest-bearing liabilities  16.1 53.9 81.3 101 135  
Balance sheet total (assets)  117 18.7 18.5 33.2 39.4  

Net Debt  -79.2 49.2 80.9 101 135  
 
See the entire balance sheet

Volume 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  11.3 0.8 -13.0 -21.9 -21.5  
Gross profit growth  0.0% -92.8% 0.0% -68.8% 2.1%  
Employees  1 1 0 0 0  
Employee growth %  0.0% 0.0% -100.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  117 19 18 33 39  
Balance sheet change%  41.8% -84.1% -1.1% 79.9% 18.8%  
Added value  11.3 0.8 -13.0 -21.9 -21.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 -1.0 -2.0 -3.0  

Profitability 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  5.3% 0.6% -10.4% -19.3% -15.7%  
ROI %  99.4% 2.9% -17.6% -23.9% -18.0%  
ROE %  14.1% -3.0% -81.8% -11.4% -58.7%  

Solidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Equity ratio %  -47.3% -85.2% -82.2% -72.6% -73.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -701.8% 6,010.4% -622.7% -459.3% -627.2%  
Gearing %  -15.3% -50.3% -95.6% -114.5% -123.2%  
Net interest  0 0 0 0 0  
Financing costs %  31.5% 8.8% 10.6% 7.1% 5.2%  

Liquidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Quick Ratio  0.5 0.1 0.2 0.3 0.3  
Current Ratio  0.5 0.1 0.2 0.3 0.3  
Cash and cash equivalent  95.3 4.7 0.4 0.0 0.0  

Capital use efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -105.0 -107.1 -85.0 -88.0 -109.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales / employee  0 0 0 0 0  
Added value / employee  11 1 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  11 1 0 0 0  
EBIT / employee  11 1 0 0 0  
Net earnings / employee  14 -2 0 0 0